Magnetic Resonance Image Compilation Was Used in Conjunction with Prostate PI-RADS v2.1 Score Has Diagnostic Relevance for Benign and Malignant Prostate Lesions

Abstract

Objective. To assess the diagnostic usefulness of magic in conjunction with PI-RADS v2.1 for prostate cancer malignant foci. Methods. A total of 202 lesions (97 transitional zone lesions and 105 peripheral zone lesions) from 198 people were investigated retrospectively using traditional MRI and magic images. Each lesion has a unique pathological consequence. Lesions T1, T2, and PD values were employed as magic observation markers. The locations of the lesions were aggregated, and the paired $t$ -test and receiver operating characteristic curve (ROC) were employed to find the indices with statistical significance in separating benign from malignant prostatic nodules (+1 point) and (−1 point) respectively. Draw a ROC curve and compare it to the PI-RADS v2.1 score using the magic positive and negative indices as well as the PI-RADS v2.1 score. By comparing the ROC curves scored separately, the diagnostic efficiency of the two scoring approaches for benign and malignant prostate lesions was investigated. Results. T2 value has the highest diagnostic efficiency among the magic observation indices. T2 value of 77 ms for transitional zone lesions and T2 value of 89 ms for peripheral zone lesions are positive indices, whereas T2 value >77 ms and T2 value >89 ms are negative indexes. PI-RADS v2.1 combines one score and magic. In the transitional zone, the sensitivity, specificity, positive predictive value, and negative predictive value of the two scoring methods were 57.52, 87.70, 76.70, and 74.6 percent and 82.50, 73.68, 95.5, and 74.7 percent, respectively, and the AUC values were 0.735 and 0.846, respectively ( $P=0.004$ ); in the peripheral zone, the AUC values were 86.15 percent, 68.42 percent, 82.4. Conclusions. Magic T2 value is a favorable sign for diagnosing benign and malignant prostate cancers when used in conjunction with PI-RADS v2.1. The end product exceeds PI-RADS v2.1 on its own, which is more useful in identifying benign and malignant prostate lesions, decreasing unnecessary puncture and alleviating patient pain.